Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma

Although there is a relationship between DNA repair deficiency and temozolomide (TMZ) resistance in glioblastoma (GBM), it remains unclear which molecule is associated with GBM recurrence. We isolated three TMZ-resistant human GBM cell lines and examined the expression of O6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair (MMR) components. We used immunohistochemical analysis to compare MutL homolog 1 (MLH1), postmeiotic segregation increased 2 (PMS2) and MGMT expression in primary and recurrent GBM specimens obtained from GBM patients during TMZ treatment. We found a reduction in MLH1 expression and a subsequent reduction in PMS2 protein levels in TMZ-resistant cells. Furthermore, MLH1 or PMS2 knockdown confered TMZ resistance. In recurrent GBM tumours, the expression of MLH1 and PMS2 was reduced when compared to primary tumours.

[1]  M. Holcik,et al.  Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma Multiforme through de-repression of Bcl-xL translation , 2013, Oncotarget.

[2]  Alireza Khoshnevisan,et al.  A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care , 2013, Oncotarget.

[3]  M. Chamberlain,et al.  Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide , 2012, Front. Oncol..

[4]  S. Asuthkar,et al.  Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis, Chemosensitivity and Radiosensitivity , 2012, Oncotarget.

[5]  S. Yip,et al.  Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide , 2012, Oncotarget.

[6]  G. Reifenberger,et al.  Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas , 2011, International journal of cancer.

[7]  H. Mehdorn,et al.  The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma , 2010, Neurological research.

[8]  A. Brandes,et al.  O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. , 2010, Neuro-oncology.

[9]  A. Jaiswal,et al.  Adenomatous polyposis coli-mediated hypersensitivity of mouse embryonic fibroblast cell lines to methylmethane sulfonate treatment: implication of base excision repair pathways. , 2007, Carcinogenesis.

[10]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[11]  Rebecca A Betensky,et al.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  P. A. Futreal,et al.  Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.

[13]  M. Weller,et al.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine , 2007, Oncogene.

[14]  S. Owatari,et al.  Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. , 2006, Blood.

[15]  W. Edelmann,et al.  Mismatch repair proteins as sensors of alkylation DNA damage. , 2006, Cancer cell.

[16]  V. O’Brien,et al.  Signalling cell cycle arrest and cell death through the MMR System. , 2006, Carcinogenesis.

[17]  Xin Huo,et al.  Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair. , 2006, DNA repair.

[18]  R. Pazdur,et al.  U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Pazdur,et al.  Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme , 2005, Clinical Cancer Research.

[20]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[22]  S. Ferrari,et al.  Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. , 2004, Genes & development.

[23]  M. Schofield,et al.  DNA mismatch repair: molecular mechanisms and biological function. , 2003, Annual review of microbiology.

[24]  J. Jiricny,et al.  Methylation‐induced G2/M arrest requires a full complement of the mismatch repair protein hMLH1 , 2003, The EMBO journal.

[25]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  池田 龍二.  Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose , 2002 .

[27]  H. Okumura,et al.  Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol a on MRP1 function , 2001, International journal of cancer.

[28]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[29]  N. Kitabatake,et al.  Toxicity of dimethyl sulfoxide as a solvent in bioassay system with HeLa cells evaluated colorimetrically with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide. , 1990, Agricultural and biological chemistry.

[30]  A. Pegg,et al.  Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.

[31]  O. Cj,et al.  Frontiers in oncology. , 1990 .

[32]  J. Garland.  The New England Journal of Medicine. , 1961, Canadian Medical Association journal.